References
- Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol. 2003;102:181–192.
- Bilano VL, Ota E, Ganchimeg T, Mori R, Souza JP. Risk factors of pre-eclampsia/eclampsia and its adverse outcomes in low- and middle-income countries: a WHO secondary analysis. PLoS One 2014;9(3):e91198. doi:10.1371/journal.pone.0091198.
- Jjankowski M. Angiogenesis inhibition and preeclampsia. J Hypertens. 2009;27:707–708.
- Lyall F, Greer IA. The vascular endothelium in normal pregnancy and preeclampsia. Rev Reprod. 1996;1(2):107–116.
- Valdes G, Kaufmann P, Corthorn J, Erices R, Brosnihan KB, Joyner-Grantham J. Vasodilator factors in the systemic and the local adaptations to pregnancy. Biol Endoc Rep. 2009;7:79.
- Seligman SP, Buyon JP. The role of nitric oxide in the pathogenesis of preeclampsia. Am J Obstet Gynecol. 1994;17:944–948.
- Sauvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaides KH. Endothelial dysfunction and raised plasma concentration of asymmetric dimetylarginine in pregnant women who subsequently developed preeclampsia. Lancet. 2003;361:1511–1517.
- Boger RH, Diemert A. The role of nitric oxide synthase inhibition by asymmetric dimethylarginine in the pathophysiology of preeclampsia. Gynecol Obstet Invest. 2009;69(1):1–13.
- Kim YJ, Park HS. Reduced L arginine level and decreased placental eNOS activity in preeclampsia. Placenta. 2006;27(4–5):438–444.
- Laskowska M, Laskowska K, Leszczyńska-Gorzelak B, Oleszczuk J. Asymmetric dimethylarginine in normotensive pregnant women with isolated fetal intrauterine growth restriction: a comparison with preeclamptic women with and without intrauterine growth restriction. J Matern Fetal Neonatal Med. 2011;24(7):936–942.
- Boger RH, Bode-Boger SM. The clinical pharmacology of L-arginine. Annu Rev Pharmacol Toxicol. 2001;41:79–99.
- Boger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase explains the “L arginine paradox” and acts as a novel cardiovascular risk factor. J Nutri. 2004;134:2842–2847.
- Neri I, Jasoni VM, Gori GF, Blasi I, Fachinnetti F. Effect of L-arginine on blood pressure in pregnancy-induced hypertension: a randomized placebo-controlled trial. J Matern Fetal Neonatal Med. 2006;19(5):277–281.
- Rytlewski K, Olszanecki R, Korbut R, Zdebski Z. Effects of prolonged oral supplementation with L-arginine on blood pressure and nitric oxide synthesis in preeclampsia. Eur J Clin Invest. 2005;35:32–37.
- Duckitt K, Harrington D. Risk factors for preeclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005;10:1136.
- ACOG Diagnosis and management of preeclampsia and eclampsia. Practice Bulletin 33; 2002.
- Vadillo-Ortega F, Perichart-Perera O, Espino S, et al. Effect of supplementation during pregnancy with L arginine and antioxidant vitamins in medical food on preeclampsia in high risk population: randomized controlled trial. BMJ. 2011;342:d2901.
- Facchinetti F, Saade GR, Neri I, Pizzi C, Longo M. L arginine supplementation in patients with gestational hypertension in pregnancy. Hypertens Pregn. 2007;26(1):121–130.
- Rytlewski K. Effects of oral l arginine on the fetal condition and neonatal outcome in preeclampsia. Preliminary report. Pharmacol Toxicol. 2006;99(2):146–152.
- Hjarturdottir S, Leifsson BG, Steinthorsdottir V. Recurrence of hypertensive disorder in second pregnancy. Am J Obstet Gynecol. 2006;194(4):916–920.
- Shim SS, Lee CH, Jun JK. Midtrimester maternal plasma concentrations of angiopoietin 1, angiopoietin 2, and placental growth factor in pregnant women who subsequently develop preeclampsia. Obstet Gynecol Sci. 2015;58(1):10–16. doi:10.5468/ogs.2015.58.1.10.
- Noris M, Todeshini M, Cassis P, et al. L arginine depletion in preeclampsia orients nitric oxide synthase toward oxidant species. Hypertension. 2004;43:614–622.
- Böger Rainer H, Ron Eyal S. L-arginine improves vascular function by overcoming the deleterious effects of ADMA, a novel cardiovascular risk factor. Altern Med Rev. 2005;10(1):14–23.
- Blum A, Porat R, Rosenschein U, et al. Clinical and inflammatory effects of dietary L-arginine in patients with intractable angina pectoris. Am J Cardiol. 1999;83:1488–1490.
- Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol. 1997;80:331–333.
- Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010;116(2Pt1):402–414. doi:10.1097/AOG.0b013e3181e9322a.